V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 210028078 | 210022584 | null | 27.8 | Curative (C) | 2017-10-30 | 2017-11-07 | CARBOPLATIN + LOMUSTINE + VINCRISTINE | 02 | N | 210025000 | UKALL 60+ TRIAL |
| 210028079 | 210013750 | 1.52 | 49.7 | Disease modification (D) | 2016-08-04 | 2016-09-08 | CYTARABINE + ETOPOSIDE | N | N | 210025389 | CLL210 TRIAL |
| 210028080 | 210028171 | 1.74 | 66 | Disease modification (D) | null | 2019-10-25 | CARBOPLATIN + ETOPOSIDE + IFOSFAMIDE | 02 | N | 210025456 | ALL MAINTENANCE |
| 210028081 | 210013752 | 1.82 | 46.3 | Palliative (P) | 2020-03-19 | 2020-03-19 | PACLITAXEL | N | N | 210025572 | ALL MAINTENANCE |
| 210028082 | 210013754 | 1.78 | 49 | null | null | 2016-12-26 | Bortezomib + MELPHALAN | Y | N | 210025600 | OFATUMUMAB |
| 210028083 | 210013754 | 1.71 | 45.3 | null | 2015-06-22 | 2015-06-22 | CLL210 TRIAL | N | N | 210025600 | ALEMTUZUMAB + CYCLO + FLUDARABINE |
| 210028084 | 210013755 | 1.63 | 78.9 | Curative (C) | 2017-03-17 | 2017-03-17 | Alemtuzumab + Cyclophos TBI Allo | N | Y | 210025657 | DAUNORUBICIN |
| 210028085 | 210013756 | 1.59 | 79.4 | null | 2019-01-04 | 2019-01-04 | CYCLET | N | N | 210025797 | TAMIGA TRIAL |
| 210028086 | 210022592 | 1.75 | null | Curative (C) | 2017-04-18 | 2017-05-21 | CNS LGG Irinotecan & Bevacizumab | N | N | 210025907 | FLUOROURACIL |
| 210028087 | 210033700 | 1.61 | 49.7 | Disease modification (D) | 2016-12-09 | 2016-12-10 | CLL210 TRIAL | N | N | 210025962 | CYTARABINE INTRATHECAL |
| 210028088 | 210013760 | null | null | Disease modification (D) | 2017-07-03 | 2017-07-06 | CYCLET | N | N | 210026481 | DABRAFENIB + TRAMETINIB |
| 210028089 | 210022594 | 1.71 | 64.4 | Curative (C) | 2018-03-07 | 2018-04-11 | PACLITAXEL | 02 | N | 210026609 | NILOTINIB |
| 210028090 | 210013762 | 1.65 | 83.8 | Disease modification (D) | 2013-04-07 | 2013-08-26 | PACLITAXEL | N | N | 210026763 | IDARUBICIN |
| 210028091 | 210022597 | 1.79 | null | null | 2017-01-11 | 2017-02-26 | ICE-R (Cycle 1) | N | N | 210027544 | BEAM |
| 210028092 | 210028177 | 0 | 112.8 | Disease modification (D) | 2015-10-27 | 2015-11-09 | Irinotecan + Modified De Gramont | N | N | 210027549 | SIOP |
| 210028093 | 210013768 | 1.42 | 59.2 | Not known (9) | 2014-02-21 | 2014-09-09 | Obinutuzumab | null | N | 210027549 | AZACITIDINE |
| 210028094 | 210013772 | 1.83 | null | Curative (C) | 2018-06-24 | 2018-06-24 | Packer Maintenance Regimen | N | N | 210027676 | BR14 TRIAL |
| 210028095 | 210013773 | 1.67 | 60.7 | Curative (C) | 2019-01-31 | 2019-02-06 | Alemtuzumab + Cyclophos TBI Allo | null | N | 210027899 | CARBOPLATIN + ETOPOSIDE + VINCRISTINE |
| 210028096 | 210013777 | 1.79 | 114 | null | 2017-09-25 | 2018-01-04 | Cyclophosphamide High Dose | 2 | N | 210027966 | CYCLOPHOSPHAMIDE + CYTARABINE + ETOPOSIDE + METHOTREXATE + NELARABINE |
| 210028097 | 210013779 | 0 | 68.5 | Adjuvant (A) | 2018-01-04 | 2018-01-05 | IPILIMUMAB + NIVOLUMAB | N | N | 210027972 | CODOX M |
| 210028098 | 210013780 | 1.68 | 61 | null | 2018-09-27 | 2018-10-12 | Alemtuzumab + Cyclophos TBI Allo | N | N | 210028000 | GEMCITABINE + OXALIPLATIN |
| 210028099 | 210013781 | null | null | Palliative (P) | 2014-05-16 | 2014-08-06 | Maintenance Therapy ALL | 02 | null | 210028000 | ALEMTUZUMAB + CYCLOPHOSPHAMIDE |
| 210028100 | 210013783 | 1.72 | 83.4 | Disease modification (D) | 2015-01-25 | 2015-02-18 | CISPLATIN + ETOPOSIDE + IFOSFAMIDE | 2 | N | 210028115 | CYCLOPHOSPHAMIDE HIGH DOSE |
| 210028101 | 210013784 | 1.77 | 89.5 | Disease modification (D) | 2016-10-25 | 2016-10-25 | ALL UKALL2003 C: Ph VII Maintenance | Y | N | 210028303 | NHL 2003 |
| 210028102 | 210013785 | 1.7 | 90.1 | Disease modification (D) | 2017-01-20 | 2017-01-20 | FLAG | N | N | 210028634 | CTD |
| 210028103 | 210013785 | 1.77 | null | Disease modification (D) | null | 2017-11-29 | CNS Medbl Std Risk Maint Cisplatin | N | N | 210028634 | IGEV R |
| 210028104 | 210022613 | 1.77 | 85.6 | Disease modification (D) | 2015-02-07 | 2015-02-10 | STS Rhabdomyosarcoma RMS 2005 IVADo | 02 | N | 210028976 | CYTARABINE + RITUXIMAB |
| 210028105 | 210013795 | null | 72.4 | Curative (C) | 2015-02-11 | 2015-04-22 | CLARITY Trial | null | N | 210029014 | ALEMTUZUMAB + CYCLO + FLUDARABINE |
| 210028106 | 210031567 | 1.7 | 86.1 | Curative (C) | 2019-04-13 | 2019-04-13 | PNET 4 HIT-SIOP Maintenance | N | N | 210029239 | OFATUMUMAB |
| 210028107 | 210022615 | 1.57 | 34.3 | Neo-adjuvant (N) | 2018-11-02 | 2018-11-02 | Packer Induction Vincristine + RT | Y | N | 210029261 | CYCLO + FLUDARABINE + RITUXIMAB |
| 210028108 | 210022615 | 1.57 | null | Palliative (P) | 2019-02-01 | 2019-02-01 | Bortezomib + Cyclophos + Dex | N | N | 210029261 | RCEOP |
| 210028109 | 210028188 | 1.81 | 68 | Curative (C) | 2016-04-16 | 2016-05-28 | Capecitabine | null | null | 210029508 | DOCETAXEL + PERTUZUMAB + TRASTUZUMAB |
| 210028110 | 210013802 | null | 60.4 | Palliative (P) | 2016-12-13 | 2016-12-24 | ICE-R | null | N | 210029535 | DOCETAXEL + PERTUZUMAB + TRASTUZUMAB |
| 210028111 | 210013802 | 1.58 | 72.6 | Curative (C) | 2016-08-29 | 2016-09-04 | Cyclophosphamide High Dose | 2 | N | 210029535 | UKALL2003 |
| 210028112 | 210028190 | 1.72 | null | Palliative (P) | 2015-03-27 | 2015-04-03 | Maintenance Therapy ALL | N | null | 210029662 | ABVD |
| 210028113 | 210013807 | 1.74 | 34 | Disease modification (D) | 2015-08-23 | 2015-08-30 | Clofarabine + Cytarabine | N | null | 210029666 | BR14 TRIAL |
| 210028114 | 210022620 | 1.77 | 45.3 | Curative (C) | 2019-06-18 | 2019-06-18 | Cladribine + Rituximab | Y | N | 210029815 | GEMCITABINE |
| 210028115 | 210013810 | 1.83 | 64 | Curative (C) | 2016-09-13 | 2016-10-18 | FCR IV - Cycle 2 onwards | N | Y | 210029888 | FLAG |
| 210028116 | 210013811 | 1.54 | null | Curative (C) | null | 2014-07-22 | Ibrutinib + Rituximab | N | N | 210029996 | PACKER MAINTENANCE |
| 210028117 | 210028192 | 1.63 | 52.6 | null | 2018-02-08 | 2018-02-10 | DABRAFENIB + TRAMETINIB | N | Y | 210030012 | CARBOPLATIN + PEMETREXED |
| 210028118 | 210013812 | 1.78 | 65 | Curative (C) | 2016-02-21 | 2016-02-21 | FCR IV - Cycle 2 onwards | 2 | N | 210030019 | CLARITY TRIAL |
| 210028119 | 210022624 | 1.62 | 23.5 | Curative (C) | 2018-05-14 | 2018-05-28 | Packer Maintenance Regimen | N | N | 210030225 | NILOTINIB |
| 210028120 | 210013815 | 1.68 | 66 | Curative (C) | 2017-11-27 | 2018-01-01 | CNS Medbl Std Risk Maint Cisplatin | 02 | N | 210030276 | CYTARABINE |
| 210028121 | 210033711 | 1.65 | 63 | Palliative (P) | 2018-11-08 | 2019-04-02 | Bevacizumab + LOMUSTINE | N | N | 210030452 | FLAG |
| 210028122 | 210028196 | 1.53 | 96.1 | Disease modification (D) | 2018-07-12 | 2018-08-01 | IDARUBICIN | Y | N | 210030490 | CLADRIBINE + RITUXIMAB |
| 210028123 | 210036201 | 1.63 | 77 | Curative (C) | 2018-05-19 | 2018-05-19 | ESHAP | 2 | N | 210030551 | IRINOTECAN + MDG |
| 210028124 | 210013820 | null | 0 | Curative (C) | 2014-08-11 | 2014-08-31 | IVE | Y | N | 210030605 | PEMBROLIZUMAB |
| 210028125 | 210013822 | 1.56 | null | Disease modification (D) | 2017-02-02 | 2017-02-11 | DOCETAXEL + PERTUZUMAB + TRASTUZUMAB | N | null | 210030647 | VAI |
| 210028126 | 210013824 | 1.66 | 98 | Curative (C) | 2017-07-06 | 2017-08-05 | ALL Int Guide B Int Maint Ph III | N | N | 210030823 | BR14 TRIAL |
| 210028127 | 210028198 | 1.72 | null | Disease modification (D) | 2016-03-19 | 2016-04-04 | Alemtuzumab + Cyclophos TBI Allo | N | N | 210030851 | DAUNORUBICIN + VNCRISTINE |